Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 19

Results For "novel"

1136 News Found

NRG Therapeutics doses first participants in landmark ALS & Parkinson’s trial
Clinical Trials | January 11, 2026

NRG Therapeutics doses first participants in landmark ALS & Parkinson’s trial

The mPTP plays a key role in mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases


Merck initiates phase 3 trial of calderasib with Keytruda QLEX for NSCLC
Clinical Trials | January 11, 2026

Merck initiates phase 3 trial of calderasib with Keytruda QLEX for NSCLC

KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer


Prokaryotics and Basilea team up to tackle deadly fungal infections
Biopharma | January 11, 2026

Prokaryotics and Basilea team up to tackle deadly fungal infections

The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections


Oculis’ Privosegtor wins FDA breakthrough therapy status for Optic Neuritis
News | January 09, 2026

Oculis’ Privosegtor wins FDA breakthrough therapy status for Optic Neuritis

The FDA designation follows visual-function results from the Phase 2 ACUITY trial


Breakthrough in PsA: Taltz plus Zepbound show major gains for patients with obesity
R&D | January 09, 2026

Breakthrough in PsA: Taltz plus Zepbound show major gains for patients with obesity

This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures


Lilly to buy Ventyx Biosciences for $1.2 billion
News | January 08, 2026

Lilly to buy Ventyx Biosciences for $1.2 billion

Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation


Amgen snaps up UK biotech Dark Blue Therapeutics in up to $840m oncology deal
Biotech | January 08, 2026

Amgen snaps up UK biotech Dark Blue Therapeutics in up to $840m oncology deal

The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation


Takeda & Protagonist submit FDA application for groundbreaking polycythemia vera therapy
R&D | January 08, 2026

Takeda & Protagonist submit FDA application for groundbreaking polycythemia vera therapy

The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production


Arrowhead Pharmaceuticals gets green light for first-of-its-kind FCS therapy
News | January 08, 2026

Arrowhead Pharmaceuticals gets green light for first-of-its-kind FCS therapy

REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS


Wockhardt files marketing authorisation application for WCK 5222 with EMA
News | January 08, 2026

Wockhardt files marketing authorisation application for WCK 5222 with EMA

WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation